These emerging medications , Semaglutide , represent a remarkable advancement in addressing obesity and possibly related disorders. They all are categorized as GLP-1 pathway agonists , indicating they to emulate the body's GLP-1 hormone , stimulating glucose production and reducing hunger . While Semaglutide each one functions somewhat similarly, t